[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical dataOn track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all pat ...

Summary of Cardinal Health's 2025 Investor Day Company Overview - **Company**: Cardinal Health (CAH) - **Event**: 2025 Investor Day held on June 12, 2025 Key Industry Insights - **Healthcare Industry Role**: Cardinal Health positions itself as a crucial link in the healthcare supply chain, connecting manufacturers to patients through a complex distribution network [7][31] - **Market Trends**: The aging population and ongoing healthcare innovations are driving demand in the healthcare sector, providing a "rising tide" of volume for the industry [32] Core Business Strategies - **Core Distribution Focus**: The company emphasizes strengthening its core distribution business, which is foundational for future growth and profitability [19][20] - **Specialty Solutions Growth**: Specialty solutions remain the highest growth priority, with a focus on organic and inorganic investments in this segment [21][50] - **Investment in Automation**: Cardinal Health is investing in automation to enhance distribution efficiency and capacity, which is critical for meeting customer needs [13][40] Financial Performance and Guidance - **Earnings Growth**: The company raised its fiscal 2025 EPS guidance and confirmed a long-term EPS growth target of 12-14% for fiscal years 2026-2028 [27][55] - **Capital Deployment**: Over the past two years, Cardinal Health has returned nearly $3 billion to shareholders while also increasing capital expenditures by over 50% compared to four to five years ago [25][24] Specialty Solutions and Partnerships - **Specialty Alliance Formation**: The formation of the Specialty Alliance aims to enhance capabilities in gastroenterology, urology, and oncology, leveraging existing infrastructure and expertise [41][90] - **Managed Service Organizations (MSOs)**: The company is expanding its MSO platforms to support independent physicians, providing back-office support and enhancing care delivery [92] Innovations and Technology - **New Distribution Centers**: Cardinal Health is launching a new flagship distribution center with advanced automation technology to improve service levels and efficiency [40][69] - **Technology Investments**: Significant investments in technology infrastructure, including a new ordering platform (Vantas HQ), are aimed at improving customer experience and operational efficiency [70] Market Position and Competitive Advantage - **Diverse Customer Base**: The company serves a wide range of customers, including independent pharmacies, health systems, and specialty practices, allowing it to adapt to various market needs [64][65] - **Strategic Sourcing**: Strong relationships with brand manufacturers and partnerships with CVS enhance product availability and cost efficiency, contributing to profitable growth [66] Future Outlook - **Growth Opportunities**: Cardinal Health anticipates significant growth in its specialty segment, with expectations of doubling the number of supported products in the next three years [98][106] - **Resilience in Cash Flow**: The company has demonstrated strong cash flow resilience, with a consistent upward trend over long periods, indicating robust operational performance [36][37] Conclusion - **Commitment to Innovation**: Cardinal Health is focused on continuous improvement and innovation to meet evolving customer and patient needs, positioning itself for sustained growth in the healthcare industry [34][55]

Core Insights - IBA has signed a contract with PET Pharm Bio to establish a PET and SPECT isotopes production center in Taipei, Taiwan, utilizing the Cyclone IKON cyclotron technology [1][4] - The new facility will produce novel radiopharmaceuticals for theranostics and targeted therapies, including isotopes such as Germanium-68, Iodine-123, Thallium-201, Zirconium-89, and Copper-64 [3][4] - The Cyclone IKON solution is expected to enhance PET Pharm Bio's capabilities in the radiopharmaceutical market, positioning it as a leader in Taiwan and Southeast Asia [4] Company Overview - PET Pharm Bio, established in 2011, focuses on the research, development, and production of radiopharmaceuticals, aiming to improve patient health and advance precision diagnosis and treatment in nuclear medicine [6] - IBA is recognized as the world leader in particle accelerator technology, providing equipment and services in proton therapy, industrial sterilization, and radiopharmaceuticals, with a workforce of approximately 2,100 employees [7] Financial Aspects - The typical end-user price for a Cyclone IKON solution ranges from EUR 10 million to EUR 15 million, depending on options and associated equipment [3]

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, on Tuesday, May 20, 2025 at 11:30 a.m. ET at the Nasdaq headquarters in New York City, New York. Investors interested in scheduling a meeting with the Company's management team sho ...

GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update. Shuttle Pharma’s recent highlights: Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma highlights include: Patient enrollment nears milestone as n ...

First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 40 patients enrolled through end of April 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumor ...

Lantheus (LNTH) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Mark Kinarney - VP - Investor RelationsBrian Markison - CEO & DirectorPaul Blanchfield - PresidentAmanda Morgan - Chief Commercial OfficerRobert Marshall - CFO & TreasurerAnthony Petrone - Managing DirectorRichard Newitter - Managing DirectorMatthew Taylor - Managing DirectorYuan Zhi - Managing Director Conference Call Participants Roanna Ruiz - Senior Managing Director, Biotechnology AnalystNone - AnalystLarry Solow - Partn ...

Lantheus (LNTH) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Good morning. Welcome to Lantheus First Quarter twenty twenty five Conference Call. All lines have been placed on mute. This call is being recorded and a replay will be available in the Investors section of the company's website approximately two hours after the completion of the call and will be archived for at least thirty days. I'll now turn the call over to Mark Kanarney, Vice President of Investor Relations. Mark? Speaker1 Thank yo ...

SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate and be available for one-on-one meetings with investors at the following upcoming investor conferences. Bank of America Global Healthcare ConferenceDate: Tuesday, May 13, 2025Format: Fireside ChatTime: 11:35 a.m. ...

SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was treated with [Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Pat ...